Impetigo – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Impetigo Market Outlook

Thelansis’s “Impetigo Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Impetigo treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Impetigo Overview

Impetigo, a prevalent infection of the superficial layers of the epidermis, is characterized by its high contagiousness and is primarily induced by gram-positive bacteria. The typical presentation involves erythematous plaques covered with a yellow crust, often accompanied by itching or pain. The infectious lesions easily spread, posing a significant contagion risk. This condition primarily affects children residing in hot and humid climates. Impetigo can manifest as either bullous or nonbullous variants. Although it commonly afflicts the facial region, it can emerge on any body area with abrasions, lacerations, insect bites, or other forms of trauma. Among pediatric skin issues, impetigo contributes to roughly 10% of cases. The incidence is equitable between genders across all age groups, but it predominantly affects males in adults. While most prevalent among 2 to 5-year-old children, impetigo can develop at any age, with the highest occurrence during the summer and fall. Bullous impetigo is particularly frequent among infants, with those under two years old constituting 90% of bullous impetigo cases. Impetigo can be categorized as either primary or secondary. The former involves the direct bacterial invasion of previously healthy skin, while the latter is triggered by infection at a prior site of skin injury. The disruption of the skin barrier provides GABHS and S. aureus access to fibronectin receptors, essential for their colonization. Common mechanisms leading to skin breakdown include trauma, cuts, insect bites, surgery, atopic dermatitis, burns, and varicella. Once a lesion is present, self-inoculation to other sites frequently occurs. Factors such as malnutrition, immunosuppression, daycare attendance, overcrowding, diabetes, and poor hygiene heighten susceptibility to impetigo. Various triggers can compromise the skin's integrity and make individuals more prone to impetigo:

1. Varicella
2. Herpes
3. Scratching
4. Lice
5. Burns
6. Trauma
7. Insect bites

Impetigo is commonly managed with topical antibiotics, alone or combined with systemic antibiotics. Effective treatment should address both S. aureus and GABHS. While impetigo can resolve independently, antibiotic therapy accelerates recovery, minimizes illness duration, and curbs lesion spread. Moreover, antibiotic intervention reduces the risk of complications involving organs like the kidneys, joints, bones, and lungs and the development of acute rheumatic fever. Topical treatment is the preferred approach for localized, uncomplicated, nonbullous impetigo. Before applying topical antibiotics like mupirocin, retapamulin, or fusidic acid, cleaning the area and removing crusts with soap and water are recommended. Untreated impetigo typically resolves within 14-21 days, with around 20% of cases spontaneously clearing up. While scarring is infrequent, some patients may experience changes in pigmentation or develop ecthyma. With treatment, complete recovery is achievable within 10 days. Neonates are at risk of developing meningitis. An uncommon complication, acute post-streptococcal glomerulonephritis, can arise 2-3 weeks after the skin infection. While most patients show improvement with treatment, a small subset might experience renal failure, particularly if the infection stems from streptococcus. Renal dysfunction tends to emerge 7-14 days after infection. Transient hematuria and proteinuria might persist for a few weeks or months. Other potential complications encompass septic arthritis, scarlet fever, sepsis, and staphylococcal scalded skin syndrome.

• In the United States, impetigo is more prevalent during the summer months. The World Health Organization also approximates that approximately 111 million children in less developed nations are simultaneously affected by streptococcal impetigo. Elevated incidences of impetigo are observed in densely populated and economically disadvantaged environments, especially under warm and humid climatic conditions, as well as within communities characterized by suboptimal hygiene practices.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: